Growth Hormone-Related Peptides

The GH–IGF-1 axis

Growth hormone signaling interacts with insulin-like growth factor 1. Hormone levels are one part of an endocrine assessment and require interpretation alongside symptoms, age and medical context.

Named research examples

Sermorelin is related to growth hormone-releasing hormone. CJC-1295 is a modified GHRH analogue. Ipamorelin acts through the growth hormone secretagogue receptor pathway. These mechanisms differ and cannot be treated as interchangeable.

What was measured in people?

A small randomized study of CJC-1295 in healthy adults measured prolonged changes in GH and IGF-1. Its short duration and laboratory endpoints do not establish improved longevity, functional recovery or durable quality of life.

Established care versus wellness use

Diagnosed endocrine disease needs specialist evaluation and an indication-specific plan. Evidence supporting treatment of an established deficiency cannot be transferred automatically to people with normal endocrine function.

Evidence limitations

Changing a hormone concentration does not show that a treatment prevents aging. Reliable studies must measure clinically meaningful outcomes, compare alternatives and evaluate long-term harms. Online combinations commonly lack that level of evidence.

Safety questions

FDA flags safety uncertainties for compounded CJC-1295 and ipamorelin. Unknown product quality and incomplete long-term data limit confident risk assessment. Discuss any existing use openly with a qualified clinician.

Regulatory context in Egypt

Authorization belongs to an exact medicine, formulation, route and indication. Egyptian registration and the clinical governance of any future REVIVE service must be verified individually. A reference to overseas research or authorization does not establish local availability.

Frequently asked questions